Clinical Trial Update: A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)

View source ↗

Summary

A Bayer-sponsored trial is recruiting to collect data on using Eylea (aflibercept) to treat retinopathy of prematurity in newborns/infants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinopathy of Prematurity

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Bayer | Conditions: Retinopathy of Prematurity, Newborns | Status: RECRUITING